PortViewPortView
Faeth Therapeutics logo

Faeth Therapeutics (FTH) Stock Analysis

NASDAQHealthcareBiotechnology

$37.46+8.55%
1-year price historyRange $7.89 – $37.40
52-week range$37.46
$7.45$37.94

What Faeth Therapeutics does

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Key metrics

Market cap
$965.67M
P/E (TTM)
-0.26
EPS (TTM)
$-141.65
Beta
-0.31
Dividend yield
0.00%
Revenue / share
$-0.86
50-day avg
$28.96
200-day avg
$21.24
52-week high
$37.94
52-week low
$7.45
CEO
Anand Parikh

ETFs linked to FTH

Broad-market and Healthcare sector ETFs an investor holding Faeth Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how FTH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze FTH in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Faeth Therapeutics?
Faeth Therapeutics trades under the ticker FTH on NASDAQ.
Which exchange is FTH listed on?
FTH is listed on NASDAQ.
What sector does Faeth Therapeutics operate in?
Faeth Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze FTH in a portfolio?
PortView shows FTH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.